Goldman Sachs Added Teva Pharmaceutical (TEVA) to its Conviction Buy List
More News related to TEVA
- Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
- Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
- Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
- Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
- Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
Goldman Sachs added Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) to its Conviction Buy List.
Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients.
Shares of TEVA fell 8.5% yesterday following disappointing data on 40mg dosage strength of Copaxone.
Related Categories
Analyst CommentsStocks Mentioned
-0.49Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
